IP Library Granted Patent US 8,435,746
Granted Patent B2
US 8,435,746 · App. 12/830,993 · Granted May 7, 2013

Aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker

Inventors: Max S. Wicha (Ann Arbor, MI); Gabriela Dontu (Ann Arbor, MI); Christophe Ginestier (Ann Arbor, MI); Emmanuelle Charafe-Jauffret (Marsielle, FR); Suling Liu (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,746
App. No.
12/830,993
Granted
May 7, 2013
Kind
B2
Abstract

The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.

Claims (10)

1. A method of detecting solid tumor stem cells in a subject and treating the subject based thereon, comprising;

a) obtaining a solid tumor tissue sample from the subject, wherein the solid tumor tissue sample comprises breast cancer or colon cancer cells;

b) determining if said solid tumor tissue sample contains solid tumor stem cells based on the presence of ALDH1 expression in said solid tumor tissue sample; and

c) treating the subject with a therapy that selectively targets the solid tumor stem cells.

2. The method of claim 1 , wherein said solid tumor tissue sample comprises breast cancer cells.

3. The method of claim 1 , wherein said solid tumor tissue sample comprises colon cancer cells.

4. The method of claim 1 , wherein said solid tumor tissue sample comprises inflammatory breast cancer cells.

5. The method of claim 1 , wherein said solid tumor tissue sample is a paraffin embedded sample.

6. The method of claim 1 , further comprising c) determining if said solid tumor tissue sample contains low levels of BRCA1 expression.

7. The method of claim 1 , wherein said therapy that selectively targets the solid tumor stem cells comprises stimulating an immune response to a solid tumor stem cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 12, 2010
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024666/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2010
From: WICHA, MAX S.; DONTU, GABRIELA; GINESTIER, CHRISTOPHE; CHARAFE-JAUFFRET, EMMANUELLE; LIU, SULING
To: THE REGENTS OF THE UNIVERSITY OF MICHGAN
Reel/Frame 024646/0459 →
Continuity (3)
Continuation 11859901 · Sep 24, 2007
Provisional Application 60846648 · Sep 22, 2006
Related Publication 20100291581A1 · Nov 18, 2010